Growing Multi-National Pharmaceutical Company Signs Agreement with eResearchTechnology for Cardiac Safety Monitoring and Informa

Growing Multi-National Pharmaceutical Company Signs Agreement with
eResearchTechnology for Cardiac Safety Monitoring and Information Distribution
Services
Award Totals Approximately $1 Million for Thorough Phase I ECG Study to be
Completed Within 90 Days 


PHILADELPHIA, Nov. 24  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has received an agreement
for approximately $1 million in cardiac safety monitoring and services from a
growing multi-national pharmaceutical organization for one of its drug
candidates in clinical trials.

The agreement covers an extensive Phase I study for which eRT is providing
comprehensive support including the provision, training and ongoing assistance
required for effective use of digital 12-lead ECG recording equipment, which is
designed to facilitate the collection of cardiac safety data that are
subsequently provided to eRT for analysis.  eRT will perform digital collection,
measurement, interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow-enabled data handling technology, the first solution
in production that was designed explicitly to meet emerging international
regulatory guidance and technical standards.  The study is targeted for
completion within 90 days of the start date, which should be at the end of the
year.

"This significant agreement is the second contract for a Thorough Phase I ECG
Study that has been awarded to eRT by this sponsor in less than five months,"
said Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT.  "Regulatory momentum has resulted in the rapid
emergence of this new study type, which requires ECG core laboratories, such as
eRT, to manage recording, analysis and distribution of large volumes of cardiac
safety data in a compressed timeframe.  eRT continues to distinguish itself as
the thought and market share leader in this important new industry segment,
which is critical to accelerating the introduction of new drugs to market
safely."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  As a result, actual results may differ materially from any financial
outlooks stated herein.  Further information on potential factors that could
affect the company's financial results can be found in the company's Reports on
Forms 10-K and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology,

Inc.



Web site:  http://www.ert.com/ 

Copyright